Prior ITP treatments most commonly prescribed to the participants were corticosteroids, intravenous immunoglobulin (IVIG), thrombopoietin receptor agonist (TPO-RA), and immunosuppressants. The gene discussed is MPL; the disease is autoimmune thrombocytopenic purpura.